SUPPLEMENTARY FIGURES
Supplementary figure S1. Verification of miR-7, miR-143, and miR203 overexpression from plasmids encoding pri-miRNAs. The miRNA expression levels were analyzed by TaqMan miRNA qPCR. Verification of pure cytoplasmic RNA samples by RT-qPCR using U48 specific TaqMan primers and probes. Total, cytoplasmic, and nuclear RNA were purified from transfected HeLa (four randomly selected samples). (B) RT-qPCR analyzing total and cytoplasmic eGFP RNA levels. Data are depicted as mean + SEM. ( * ) P < 0.05, ( * * * ) P < 0.001, (ns) not significant. 
SUPPLEMENTARY MATERIALS AND METHODS

Vector construction
For expression of TuDs, expression plasmids and lentiviral vectors were used. To create expression vectors expressing an eGFP reporter gene fused to WPRE from a CMV promoter, the eGFP-WPRE-MCS expression cassette was amplified from pCCL-eGFP-WPRE-1xTuD21 using the primers 5137 and 5138 ( and -143, TuD-encoding DNA sequences were synthesized and cloned into pUC57 by GenScript (Piscataway, NJ, USA). The TuD DNA sequences were designed to include terminal NheI and AscI restriction sites, which allowed insertion of the TuDs into NheI/MluI-digested pT2/CMV-eGFP-WPRE-MCS.SV40-neo, pT2/CMV-eGFP-WPRErev-MCS.SV40-neo, and pT2/CMV-eGFP-MCS.SV40-neo, resulting in vectors designated pT2/CMV-eGFP-WPRE-TuD.SV40-neo, pT2/CMVeGFP-WPRErev-TuD.SV40-neo, and pT2/CMV-eGFP-TuD.SV40-neo respectively.
For construction of vectors encoding the eGFP-TuD-WPRE expression cassette, WPRE including flanking sequenced were PCR-amplified using the primers 5249 and 5250 (table S1 ) and inserted into AgeI-digested pT2/CMV-eGFP-TuD.SV40-neo vectors encoding TuDs targeting miR-7, miR-16, and miR-21. The resulting plasmids were designated pT2/CMV-eGFP-TuD-WPRE.SV40-neo. according to GenBank accession number J04514) were generated by replacing WPRE in the pT2/CMV-eGFP-WPRE-TuD.SV40-neo plasmids, containing TuDs targeting miR-7 or miR-16, with WPREΔP. The WPREΔP DNA fragment was generated from pT2/CMV-eGFP-WPRE-MCS.SV40-neo by an overlap extension PCR using the primers 5194, 5195, 5196, and 5138 (table S1 ). The PCR fragment was inserted into BsrGI/NheI-digested pT2/CMV-eGFP-WPRE-TuD.SV40-neo, resulting in vectors designated pT2/CMV-eGFP-WPREΔP-TuD.SV40-neo.
TuD expression vectors with a deletion of the hairpin structure of the WPRE α-subunit (WPREΔαhairpin) (nt 1396-1476 according to GenBank accession number J04514) and vectors encoding the WPREγ-, WPREα-, WPREβ-, WPREγα-, WPREγβ-, and WPREαβ-subunits previously described by Donello et al. (Donello et al. 1998) were generated by PCR-amplification of the WPREvariants using the primers specified in table S1. The PCR products were inserted into BsrGI/NheIdigested pT2/CMV-eGFP-WPRE-TuD.SV40 resulting in vectors designated pT2/CMV-eGFPWPREΔαhairpin-TuD.SV40-neo, pT2/CMV-eGFP-WPREγ-TuD.SV40-neo, pT2/CMV-eGFP-WPREα-TuD.SV40-neo, pT2/CMV-eGFP-WPREβ-TuD.SV40-neo, pT2/CMV-eGFP-WPREγα-TuD.SV40-neo, pT2/CMV-eGFP-WPREγβ-TuD.SV40-neo, and pT2/CMV-eGFP-WPREαβ-TuD.SV40-neo.
Lentiviral vectors encoding TuDs targeting miR-16, -21, and -203 fused to eGFP and WPRE
(pCCL/PGK-eGFP-WPRE-TuD) were made as described Hollensen et al. 2013 ). To generate lentiviral vectors encoding TuDs targeting miR-16, -21, and -203 fused directly to eGFP, pCCL/PGK-eGFP-WPRE-TuD vectors were digested with EcoRI and religated. The resulting plasmids were designated pCCL/PGK-eGFP-TuD.
Except vectors for evaluation of TuD7 efficiency, vectors for expression of pri-miRNAs from a CMV promoter (pT/CMV-miR.SV40-neo) and psiCHECK vectors carrying perfect miRNA target sites in the 3'-UTR of the RLuc reporter gene (psiCHECK-miRtarget) were previously described (Primo et al. 2012; Bak et al. 2013; Hollensen et al. 2013) . Vectors for expression of pri-miR7 were made by PCR amplification of pri-miR7 from genomic DNA from RPE cells using the primers 5119 and 5120 (table   S1 ). The PCR product was inserted into NotI-digeted pT2/CMV-primiR146a.SV40-neo replacing primiR-146a with pri-miR-7. For construction of psiCHECK vectors carrying a perfect miR-7 target complementary sense (primer #5121, table S1) and antisense (primer #5122, table S1) oligonucleotides were annealed and subsequently cloned into XhoI/NotI-digested psiCHECK-2 (Promega, Madison, WI, USA)
All plasmids were verified by sequencing (GATC Biotech, Constance, Germany).
Cell culturing
HEK-293 and HeLa cells were cultured at 37°C in 5% (v/v) CO2 and maintained in Dulbecco's modified Eagle's medium (Lonza, Basel, Switzerland) supplemented with 5% fetal calf serum (Sigma-Aldrich, Milwaukee, WI, USA), penicillin (100 U/mL) (Sigma-Aldrich, Milwaukee, WI, USA), and streptomycin (0.1 mg/mL) (Sigma-Aldrich, Milwaukee, WI, USA).
Lentiviral production
Third-generation lentiviral vectors were produced in HEK-293T cells, as previously described (Jakobsen et al. 2009 ). One day prior to transfection, HEK-293T cells were seeded in 10-cm dishes at a density of 4 × 10 6 cells/dish. Transfections were carried out with 3.75 μg pMD.2G, 3 μg pRSV-Rev, 13 μg pMDLg/pRRE, and 13 μg lentiviral transfer vector using a standard calcium phosphate transfection protocol. Medium was changed one day after transfection. Two days after transfection viral supernatants were harvested and filtered through 0.45 µm filters (Sarstedt, Nümbrecht, Germany). All lentiviral preparations were made in triplicates.
Titer assay
Flow cytometric measurements of eGFP expression were used to determine viral titers of all lentiviral preparations. One day before transduction, HeLa cells were seeded at a density of 1 × 10 5 cells/well in 6-well plates. The transduction was carried out with 10 2 -, 10 3 -, and 10 4 -fold dilutions of viruscontaining supernatant. Both supernatants and growth medium were supplemented with 8 µg/ml polybrene (Sigma-Aldrich, Milwaukee, WI, USA). Medium was changed one day after transduction.
One week after, transduced cells were harvested and prepared for flow cytometry by fixation in 4 % formaldehyde. eGFP expression levels were analyzed on a BD LSRFortessa (BD Biosciences, Franklin Lakes, NJ, USA) and viral titers were calculated based on samples with between 2.4% and 10.1% eGFP positive cells using the formula: titer (TU/ml) = F·Cn·DF/V, where F represents the frequency of eGFP positive cells, Cn the total number of target cells counted the day transduction was carried out, DF the dilution factor of the virus, and V the volume of transducing inoculum.
Dual-Glo Luciferase Assays
Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA) was used to evaluate the miRNA suppression potential of the TuD miRNA inhibitors after delivery of the TuDs by both plasmid transfection and lentiviral transduction. In both cases HEK-293 cells were seeded at a density of 3000 cells/well in white 96-well plates. For plasmid delivery of the TuDs, co-transfections were carried out one day after the cells were seeded with 34 ng of TuD miRNA inhibitor plasmid, 6 ng psiCHECK reporter plasmid, and for miR-7, -143, and -203 3 ng of miRNA expression vector using XtemeGENE 9 (Roche, Basel, Switzerland) according to manufacturer's protocol. For lentiviral delivery of the TuDs, the HEK-293 cells were transduced one day after seeding using a MOI of 100.
The MOIs were calculated based on titers determined by flow cytometry. One day after transduction, transfections were carried out with 6 ng psiCHECK reporter plasmid and for miR-203 3 ng of miRNA expression vector using X-temeGENE 9 (Roche, Basel, Switzerland) according to manufacturer's protocol. For evaluation of miRNA suppression after knockdown of the P-body associated proteins 
Polysome profiling
Translation efficiency of eGFP-encoding mRNA was analyzed by polysome profiling basically as previously described (Damgaard and Lykke-Andersen 2011) . Briefly, one day prior to transfection, HeLa cells were seeded at a density of 1 × 10 6 cells/dish in 10 cm dishes. Transfections were carried out with 3 µg expression vector using X-temeGENE 9 (Roche, Basel, Switzerland) according to manufacturer's protocol. Two days after transfection, HeLa cells were incubated in medium containing 100 µg/ml cyclohexamide (CHX) for 3 min at 37°C. Afterwards, cells were washed once in PBS containing with 100 µg/ml CHX and kept on ice. Cells were lysed directly in the 10-cm dishes using 900 µl polysome extraction buffer (PEB; 10 mM Tris (pH 7.5), 0.5% Triton X-100, 7.5 mM MgCl2, 100 μg/mL cycloheximide, 150 mM NaCl, 500 µg/mL Heparin), scraped off, and incubated on ice for 5 min. Debris was removed by centrifugation at 12,000 rpm for 10 min at 4°C, and 800 µl cleared lysate was loaded on sucrose gradients of 10-50% consistency (Teledyne-Isco gradient maker). Subsequently, the content of the cleared lysate was separated according to density by ultracentrifugation at 35,000 rpm at 4°C for 150 min, and 12 1-ml fractions were collected using a Teledyne-Isco fractionation system. For purification of RNA, 400 µl of each fraction was added 600 μL of 8 M guanidine HCl and 600 μL of isopropanol and incubated at -20°C overnight. Samples were centrifuged at 12,000 rpm for 25 min. Subsequently, pellets were resuspended in 500 µl TRI Reagent (Sigma-Aldrich, Milwaukee, WI, USA), and RNA was purified according to manufacturer's protocol.
Finally, equal volumes of RNA were treated with DNase I (Life Technologies, Carlsbad, CA, USA) and eGFP RNA levels were analyzed by quantitative Real-Time PCR.
FISH and immunostaining
For determination of RNA levels and the nuclear RNA export rate by RNA FISH, HeLa cells were seeded at a density of 3 × 10 4 cells/well on 18 mm cover slips in 12-well plates one day before transfection. Transfections were carried out using 200 ng or 400 ng expression vector and 1.5 µg XtremeGENE 9 (Roche, Basel, Switzerland). Two days after transfection cells were washed twice in PBS and fixated in 4% paraformaldehyde in PBS for 20 min. Subsequently, cells were washed twice in PBS and permeabilized and stored in 70% ethanol at 4°C. RNA FISH was performed by rehydration of cells in PBS for 5 min at room temperature and incubation in prehybridization buffer (2xSSC containing, 50% formamide) for 10 min at room temperature. Hybridization was carried out in a humidified hybridization chamber using 25 µl hybridization solution (10 ng/µl probe (Cy5-labeled eGFP specific probes, table S2), 0.2 µg/ml E. coli tRNA, 0.2 µg/ml salmon sperm DNA (ssDNA), 50% formamide, 2xSSC, 2 mg/ml bovine serum albumin (BSA)) per coverslip. For all probes, Cy5 fluorophores were conjugated to amino-allyl-modified thymidines as previously described (Damgaard and Lykke-Andersen 2011) . After hybridization for 3 hours at 37°C, cover slips were washed twice in prehybridization buffer for 20 min at 37°C, once in 2xSSC for 10 in at room temperature, and once in PBS for 10 in at room temperature. Nuclei were stained in PBS containing 1 mg/ml DAPI for 2 min at room temperature. The cover slips were washed twice in PBS, once in H2O
and mounted using ProLONG GOLD (Life Technologies, Carlsbad, CA, USA). Cells were visualized using fluorescence microscopy (Zeiss Axiovert 200m with Coolsnap HQ camera).
Co-localization of TuD transcripts and P-bodies was evaluated by combined FISH using probes specific for eGFP-encoding RNA and immunostaining using hDcp1a antibodies. One day prior to transfection, HeLa cells were seeded at a density of 1 × 10 6 cells/dish in 10-cm dishes. Transfections were carried out with 3 µg TuD-encoding expression vector and 300 ng plasmid encoding pri-miR7 using 6 µl TurboFect Transfection Reagent (Life Technologies, Carlsbad, CA, USA) according to manufacturer's protocol. Two days after transfection, HeLa cells were sorted into three groups with low, intermediate, and high eGFP expression on a BD FACSAriaIII (BD Biosciences, Franklin Lakes, NJ, USA) and seeded on 18 mm cover slips in 12-well plates. One day after sorting, cells were washed twice in PBS, fixated in 4% paraformaldehyde in PBS for 20 min, and stored in 70% ethanol at 4°C. FISH staining was carried out as described above. However, the cells were permeabilized in 0.2% triton X in PBS for 10 min at room temperature before incubation in prehybridization buffer.
Immunostaining was carried out after hybridization with eGFP specific probes and before nuclei staining with DAPI. Cells were washed in PBS containing 1% BSA for 10 min and subsequently incubated 1 hour a room temperature with 400 µl rabbit anti-hDcp1a (antibodies were generously provided by Professor Jens Lykke-Andersen, University of California San Diego, USA) diluted 1:2000 in PBS containing 1% BSA. After two washes in PBS and one in PBS containing 1% BSA, the cells were incubated in 400 µl Alexa488-labeled secondary antibodies (Waltham, Massachusetts, USA) diluted 1:1000 in PBS containing 1% BSA for 1 hour at room temperature. Finally, cells were washed twice in PBS, the nuclei were stained with DAPI, and the coverslips were mounted as described above. 
Purification of total and cytoplasmic RNA
For analysis of nuclear export of TuD-containing mRNA by separation of nuclear and cytoplasmic mRNA, HeLa cells were seeded at a density of 7 × 10 5 cells/dish in 10 cm dishes one day prior to transfection. Transfections were carried out using 2 µg SB transposon vector and 4 µl Turbofect Transfection Reagent (Life Technologies, Carlsbad, CA, USA). Two days after transfection cells were washed in PBS, added 800 µl PBS, and scraped off. 200 µl of the cell solution was centrifuged at 12,000 rpm for 10 sec at 4°C, and pellets were used for purification of total RNA using 1 ml of TRI Reagent (Sigma-Aldrich, Milwaukee, WI, USA) according to manufacturer's protocol. The remaining 600 µl of the cell solution was used for subcellular fractionation of nuclear and cytoplasmic RNA after centrifugation at 12,000 rpm for 10 sec at 4°C. Cell pellets were lysed by resuspension in 300 µl lysis buffer (20 mM Tris-HCl (pH 7.5), 140 mM NaCl, 1 mM EDTA, 0.5% Igepal-630 (Nonidet P-40)), incubation on ice for 2 min and centrifugation at 1000 g for 4 min at 4°C. Cytoplasmic RNA was purified from supernatants using 1 ml TRI Reagent (Sigma-Aldrich, Milwaukee, WI, USA).
Pellets were washed once in 500 µl lysis buffer, and nuclear RNA was purified from the pellets by using 1 ml TRI Reagent (Sigma-Aldrich, Milwaukee, WI, USA). All RNA purifications using TRI Reagent (Sigma-Aldrich, Milwaukee, WI, USA) were performed according to manufacturer's protocol. eGFP and U48 RNA levels were evaluated by RT-qPCR.
Overexpression and purification of miRNAs
For evaluation of miRNA expression levels, HEK-293 cells were seeded at a density of 2 × 10 5 cells/well in 6-well plates. One day after seeding the cells, transfections were carried out using 200 ng plasmids encoding pri-miR-7, -16, or -143/145 and 800 ng of pT2/CMV-eGFP-MCS.SV40-neo as stuffer DNA. 1 µg of pT2/CMV-eGFP-MCS.SV40-neo were used for transfection of control cells. XtremeGENE 9 (Roche, Basel, Switzerland) was used as transfection reagent to manufacturer's protocol. Two days after transfection, RNA was purified using 0.5 ml of TRI Reagent (SigmaAldrich, Milwaukee, WI, USA) according to manufacturer's protocol.
Quantitative PCR
For quantification of RNA levels, RT-qPCR was carried out. All RNA samples were treated with DNase I (Life Technologies, Carlsbad, CA, USA). First-strand cDNA synthesis was carried out using the Maxima First Strand cDNA Synthesis Kit for qPCR (Life Technologies, Carlsbad, CA, USA) for mRNA quantification and TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) for quantification of miRNAs and U48 according to manufacturer's protocols.
Subsequently, qPCR reactions were prepared using the Maxima Probe qPCR Master Mix (Life Technologies, Carlsbad, CA, USA) and TaqMan primers and probes specific for eGFP (eGFP forward: 5'-ctgctgcccgacaaccac-3', eGFP reverse: 5'-tgtgatcgcgcttctcgtt-3', eGFP probe: 5'-Famacctgagcacccagtccgccct-Tamra-3'), RPLP0 (RPLP0 forward: 5'-ggcgacctggaagtccaact-3', RPLP0
reverse: 5'-ccatcagcaccacagccttc-3', RPLP0 probe: 5'-Fam-atctgctgcatctgcttggagccca-Tamra-3'), miR-7, -16, -143, or U48 (Applied Biosystems, Foster City, CA, USA). RPLP0 and U48 was used as reference genes. Finally, RNA levels were quantified using a LightCycler 480 (Roche, Basel, method. 5120 pri-miR7 (human) (as) 5'-aaa gcg gcc gcg caa tgt taa gtg tca aga aaa atg -3'
Statistical analysis
psiCHECK-miR7target
5121 miR-7 target (human) (s) 5'-tcg agt aaa caa caa aat cac tag tct tcc aag g -3'
5122 miR-7 target (human) (as) 5'-ggc ccc ttg gaa gac tag tga ttt tgt tgt tta c -3' pT2/CMV-eGFP-WPRE-MCS.SV40-neo 5137 eGFP (s) 5'-aaa gcg gcc gct ccg gaa tgg tga gca agg gcg agg ag -3' 5138 MCS (as) 5'-aaa gcg gcc gca ccg gta cgc gtc ctg cag ggc tag cgg tgg tct cat acg gta ccg -3' pT2/CMV-eGFP-MCS.SV40-neo 5137 eGFP (s) 5'-aaa gcg gcc gct ccg gaa tgg tga gca agg gcg agg ag -3' 5169 WPRE (as) 5'-aaa aag cta gct cgg aat tcc ctc gag gcc g -3'
pT2/CMV-eGFP-WPRErev-MCS.SV40-neo 5156 WPRE (s) 5'-aaa aag cta gca gcg gcc tcg agg gaa ttc cga -3' 5157 WPRE (as) 5'-aaa tgt aca agt aag tac cga gct cga att ccc g -3'
pT2/CMV-eGFP-TuD-WPRE.SV40-neo 5249 WPRE (s) 5'-aaa acc ggt ggc ctc gag gga att ccg a -3' 5250 WPRE (as) 5'-aaa acc ggt gta ccg agc tcg aat tcc cg -3' pT2/CMV-eGFP-WPREΔP-TuD.SV40-neo 5194 WPRE (s) 5'-cga gct gta caa gta aag cg -3' 5195 WPREΔP with overlap (as) 5'-gac aac acc acg gaa ttg tc -3' 5196 WPREΔP with overlap (s) 5'-gac aat tcc gtg gtg ttg tct ggc tgc tcg cct gtg ttg -3' 5138 MCS (as) 5'-aaa gcg gcc gca ccg gta cgc gtc ctg cag ggc tag cgg tgg tct cat acg gta ccg -3' pT2/CMV-eGFP-WPREΔαhairpin-TuD.SV40-neo 5'-aaa tgt aca agt aaa gcg gcc tc -3' 5255 WPREmut1 (as) 5'-aat agg gag ggg gaa agc gaa ag -3' 5256 WPREmut1 (s) 5'-tcg ctt tcc ccc tcc cta ttg ttg tcg ggg aag ctg acg tc -3' 5254 WPRE (NheI) (as) 5'-aaa aag cta gcg gtg gtc tca tac g -3'
pT2/CMV-eGFP-WPREγ-TuD.SV40-neo 5253 WPRE (BsrGI) (s) 5'-aaa tgt aca agt aaa gcg gcc tc -3' 5264 WPREγ (NheI) (as) 5'-aaa aag cta gcg gtg gtc tca tac ggt acc gag ctc gaa ttc ccg ata cgc cac gtt gcc tga caa c -3' pT2/CMV-eGFP-WPREα-TuD.SV40-neo 5265 WPREα (BsrGI) (s) 5'-aaa tgt aca agt aaa gcg gcc tcg agg gaa ttc cga ggt gtg cac tgt gtt tgc tg -3' 5266 WPREα (NheI) (as) 5'-aaa aag cta gcg gtg gtc tca tac ggt acc gag ctc gaa ttc ccg atc atg gaa agg acg tca gct t -3'
pT2/CMV-eGFP-WPREβ-TuD.SV40-neo 5267 WPREβ (BsrGI) (s) 5'-aaa tgt aca agt aaa gcg gcc tcg agg gaa ttc cga gct gct cgc ctg tgt tgc cac -3' 5254 WPRE (NheI) (as) 5'-aaa aag cta gcg gtg gtc tca tac g -3'
pT2/CMV-eGFP-WPREγα-TuD.SV40-neo 5253 WPRE (BsrGI) (s) 5'-aaa tgt aca agt aaa gcg gcc tc -3' 5266 WPREα (NheI) (as) 5'-aaa aag cta gcg gtg gtc tca tac ggt acc gag ctc gaa ttc ccg atc atg gaa agg acg tca gct t -3' pT2/CMV-eGFP-WPREγβ-TuD.SV40-neo 5253 WPRE (BsrGI) (s) 5'-aaa tgt aca agt aaa gcg gcc tc -3' 5268 WPREγ (as) 5'-acg cca cgt tgc ctg aca ac -3' 5269 WPREβ (s) 5'-gtt gtc agg caa cgt ggc gtg ctg ctc gcc tgt gtt gcc ac -3' 5254 WPRE (NheI) (as) 5'-aaa aag cta gcg gtg gtc tca tac g -3'
pT2/CMV-eGFP-WPREαβ-TuD.SV40-neo 5265 WPREα (BsrGI) (s) 5'-aaa tgt aca agt aaa gcg gcc tcg agg gaa ttc cga ggt gtg cac tgt gtt tgc tg -3'
